{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epoetin+alfa+once+weekly&page=2", "query": { "intervention": "Epoetin alfa once weekly", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 41, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epoetin+alfa+once+weekly&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epoetin+alfa+once+weekly&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T01:23:38.067Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00077623", "title": "A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "epoetin alfa or beta", "type": "DRUG" }, { "name": "methoxy polyethylene glycol-epoetin beta (Mircera)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 572, "start_date": "2004-03", "completion_date": "2005-09", "has_results": true, "last_update_posted_date": "2016-05-25", "last_synced_at": "2026-10-05T01:23:38.067Z", "location_count": 17, "location_summary": "Hot Springs, Arkansas • Los Angeles, California • Riverside, California + 14 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077623" }, { "nct_id": "NCT03169881", "title": "Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurocognitive", "Neuroprotective", "Neonatal", "Neurodevelopmental Impairment" ], "interventions": [ { "name": "Darbepoetin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NICHD Neonatal Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Hour", "maximum_age": "24 Hours", "sex": "ALL", "summary": "1 Hour to 24 Hours" }, "enrollment_count": 650, "start_date": "2017-09-20", "completion_date": "2025-05-12", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-05T01:23:38.067Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT03169881" }, { "nct_id": "NCT00058331", "title": "Epoetin Alfa in Treating Anemia in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "epoetin alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 365, "start_date": "2003-06", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2016-07-18", "last_synced_at": "2026-10-05T01:23:38.067Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058331" }, { "nct_id": "NCT03552393", "title": "Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Renal Insufficiency, Chronic" ], "interventions": [ { "name": "Mircera", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Months to 17 Years" }, "enrollment_count": 40, "start_date": "2018-08-03", "completion_date": "2021-07-19", "has_results": true, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-10-05T01:23:38.067Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Loma Linda, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "West Orange", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03552393" }, { "nct_id": "NCT00077610", "title": "A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "Epoetin alfa or beta", "type": "DRUG" }, { "name": "RO0503821 (1x/2 Weeks)", "type": "DRUG" }, { "name": "RO0503821 (1x/4 Weeks)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 673, "start_date": "2004-02", "completion_date": "2005-08", "has_results": true, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-10-05T01:23:38.067Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Encino", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077610" }, { "nct_id": "NCT00090753", "title": "A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "Methoxy Polyethylene Glycol-Epoetin Beta", "type": "DRUG" }, { "name": "Epoetin alfa", "type": "DRUG" }, { "name": "Epoetin beta", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1228, "start_date": "2004-10", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2012-02-14", "last_synced_at": "2026-10-05T01:23:38.067Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00090753" }, { "nct_id": "NCT01099202", "title": "Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Procrit (epoetin alfa)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 109, "start_date": "2003-03", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2012-08-27", "last_synced_at": "2026-10-05T01:23:38.067Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01099202" }, { "nct_id": "NCT00014222", "title": "Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "epoetin alfa", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "NCIC Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "FEMALE", "summary": "Up to 60 Years · Female only" }, "enrollment_count": 2104, "start_date": "2000-12-04", "completion_date": "2014-03-17", "has_results": true, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-10-05T01:23:38.067Z", "location_count": 44, "location_summary": "Fort Smith, Arkansas • Little Rock, Arkansas • La Jolla, California + 39 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Greenwich", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014222" }, { "nct_id": "NCT00003600", "title": "Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Breast Cancer", "Chronic Myeloproliferative Disorders", "Drug/Agent Toxicity by Tissue/Organ", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous Condition", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "epoetin alfa", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 344, "start_date": "1998-12", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-10-05T01:23:38.067Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003600" }, { "nct_id": "NCT00070382", "title": "Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "darbepoetin alfa", "type": "DRUG" }, { "name": "epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2003-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-05T01:23:38.067Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00070382" } ] }